Myriad Genetics (MYGN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.25
- Estimate
- -$0.06
- Surprise
- -332.7%
- Score at report (before → after)
- 4.7 → 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Myriad Genetics (MYGN) reported a wider loss than forecast — adjusted EPS of -$0.25 against the -$0.06 estimate (a 332.7% shortfall). TrendMatrix's engine moved from Sell (4.7/10) to Hold at 5.3/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MYGN Sell at 4.5/10.
2 of the last 4 quarters beat the estimate; this quarter's -332.7% surprise compares with a +6.5% four-quarter average. Next scheduled report: 2027-02-23.
What argues against it
- Target reached (-7.8% upside)
- Quality below floor (3.2 < 4.0)
- Value-trap signals (2/5): Revenue declining (-62.2% YoY), High leverage (D/E 5.3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.57
- Stop
- $5.18
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
MYGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $542.9M
- P/E (fwd)
- -9.1
- 52-week range
- $2.74–$8.09
- Off 52-week high
- 31.1%
- RSI (14)
- 36
- Volume vs avg
- 0.35×
- Score today
- 4.5/10